ORGO

Organogenesis Holdings Inc

ORGO, USA

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

https://organogenesis.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ORGO
stock
ORGO

Organogenesis: High-Tech Skin Substitute Company On Sale (NASDAQ:ORGO) Seeking Alpha

Read more →
ORGO
stock
ORGO

Investors in cash trouble should check out Organogenesis Holdings Inc (ORGO) Setenews

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$8.5

Analyst Picks

Strong Buy

3

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.61

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

5.59 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

4.23 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

0.56 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.32

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 58.37% of the total shares of Organogenesis Holdings Inc

1.

Soleus Capital Management, L.P.

(9.7301%)

since

2025/06/30

2.

Morgan Stanley - Brokerage Accounts

(9.5035%)

since

2025/06/30

3.

First Light Asset Management, LLC

(5.3423%)

since

2025/06/30

4.

Vanguard Group Inc

(4.0966%)

since

2025/06/30

5.

BlackRock Inc

(3.7317%)

since

2025/06/30

6.

Deutsche Bank AG

(2.584%)

since

2025/06/30

7.

Xtrackers S&P 500 Swap ETF 1C

(2.5603%)

since

2025/07/31

8.

Dimensional Fund Advisors, Inc.

(2.4473%)

since

2025/06/30

9.

Assenagon Asset Management SA

(2.2528%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(1.5235%)

since

2025/07/31

11.

iShares Russell 2000 ETF

(1.3445%)

since

2025/08/31

12.

Geode Capital Management, LLC

(1.3195%)

since

2025/06/30

13.

State Street Corp

(1.1892%)

since

2025/06/30

14.

Charles Schwab Investment Management Inc

(0.7557%)

since

2025/06/30

15.

Renaissance Technologies Corp

(0.6337%)

since

2025/06/30

16.

Northern Trust Corp

(0.6213%)

since

2025/06/30

17.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6121%)

since

2025/07/31

18.

AQR Capital Management LLC

(0.5653%)

since

2025/06/30

19.

Fidelity Small Cap Index

(0.5396%)

since

2025/06/30

20.

Vanguard Explorer Inv

(0.5266%)

since

2025/06/30

21.

iShares Russell 2000 Growth ETF

(0.4843%)

since

2025/08/31

22.

D. E. Shaw & Co LP

(0.4833%)

since

2025/06/30

23.

Connor Clark & Lunn Inv Mgmt Ltd

(0.4676%)

since

2025/06/30

24.

DFA US Targeted Value I

(0.4418%)

since

2025/07/31

25.

State Of Wisconsin Investment Board

(0.4156%)

since

2025/06/30

26.

UBS Group AG

(0.3936%)

since

2025/06/30

27.

Bank of America Corp

(0.379%)

since

2025/06/30

28.

Dimensional US Targeted Value ETF

(0.3661%)

since

2025/08/29

29.

Wellington Management Company LLP

(0.3306%)

since

2025/06/30

30.

Schwab Small-Cap Equity

(0.3016%)

since

2025/06/30

31.

Fidelity Extended Market Index

(0.3%)

since

2025/07/31

32.

DFA US Small Cap I

(0.2845%)

since

2025/07/31

33.

Vanguard Strategic Equity Inv

(0.2633%)

since

2025/06/30

34.

Schwab US Small-Cap ETFâ„¢

(0.2592%)

since

2025/08/30

35.

Dimensional US Small Cap ETF

(0.2581%)

since

2025/08/29

36.

Vanguard Russell 2000 ETF

(0.2558%)

since

2025/07/31

37.

DFA US Micro Cap I

(0.2357%)

since

2025/07/31

38.

State St Russell Sm Cap® Indx SL Cl I

(0.2105%)

since

2025/08/31

39.

Lazard US Sm Cap Eq WW Dist EUR

(0.2088%)

since

2025/05/31

40.

NT Quality Small Cap Value

(0.1515%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.16

Latest Release

Date

2025-09-30

EPS Actual

0.1775

EPS Estimate

0.0629

EPS Difference

0.1146

Surprise Percent

182.194%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(7)
Dividend
Decent Dividend Payer(3.5)
Economic Moat
Wide Moat Company(7)
GARP
Fair GARP(6)
Growth
Moderate Growth(4.5)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(4)
Quality
High Quality(7.5)
Value
Undervalued(8.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.